Effects of Y Box Binding Protein-1 in Progression and Prognosis of Cholangiocarcinoma

References

• Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise. Oncologist. 2016;21(5):594–599. doi: 10.1634/theoncologist.2015-0446.
   PubMed Web of Science ®Google Scholar
• Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234(4):507–517.
   PubMed Web of Science ®Google Scholar
• Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):88–98. doi: 10.1053/j.gastro.2012.04.008.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178–1188. doi: 10.1002/hep.28744.
   PubMed Web of Science ®Google Scholar
• Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transpl. 2000;6(6 Suppl. 2):S30–S34. doi: 10.1053/jlts.2000.18688.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. doi: 10.1056/NEJMoa0908721.
   PubMed Web of Science ®Google Scholar
• Lasham A, Print CG, Woolley AG, Dunn SE, Braithwaite AW. YB-1: Oncoprotein, prognostic marker and therapeutic target? Biochem J. 2013;449(1):11–23. doi: 10.1042/BJ20121323.
   PubMed Web of Science ®Google Scholar
• Wolffe AP, Tafuri S, Ranjan M, Familari M. The Y-box factors: a family of nucleic acid binding proteins conserved from Escherichia coli to man. New Biol. 1992;4(4):290–298.
   PubMedGoogle Scholar
• Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003;25(7):691–698. doi: 10.1002/bies.10300.
   PubMed Web of Science ®Google Scholar
• Mertens PR, Harendza S, Pollock AS, Lovett DH. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem. 1997;272(36):22905–22912.
   PubMed Web of Science ®Google Scholar
• Lasham A, Moloney S, Hale T, et al. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem. 2003;278(37):35516–35523. doi: 10.1074/jbc.M303920200.
   PubMed Web of Science ®Google Scholar
• En-Nia A, Yilmaz E, Klinge U, Lovett DH, Stefanidis I, Mertens PR. Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem. 2005;280(9):7702–7711. doi: 10.1074/jbc.M413353200.
   PubMed Web of Science ®Google Scholar
• Das S, Chattopadhyay R, Bhakat KK, et al. Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress. J Biol Chem. 2007;282(39):28474–28484. doi: 10.1074/jbc.M704672200.
   PubMed Web of Science ®Google Scholar
• Stein U, Jurchott K, Walther W, Bergmann S, Schlag PM, Royer HD. Hyperthermia-induced nuclear translocation of transcription factor YB1 leads to enhanced expression of multidrug resistance related ABC transporters. J Biol Chem. 2001;276(30):28562–28569. doi: 10.1074/jbc.M100311200.
   PubMed Web of Science ®Google Scholar
• Evdokimova V, Tognon C, Ng T, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009;15(5):402–415. doi: 10.1016/j.ccr.2009.03.017.
   PubMed Web of Science ®Google Scholar
• Tian F, Li D, Chen J, et al. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma. Eur J Cancer. 2013;49(7):1771–1780. doi: 10.1016/j.ejca.2012.12.015.
   PubMed Web of Science ®Google Scholar
• Xu J, Li D, Li X, et al. 67 laminin receptor promotes the malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma. Dig Liver Dis. 2014;46(8):750–757. doi: 10.1016/j.dld.2014.03.017.
   PubMedGoogle Scholar
• Liu W, Tian F, Jiang P, et al. Aberrant expression of lamininγ2 correlates with poor prognosis and promotes invasion in extrahepatic cholangiocarcinoma. J Surg Res. 2014;186(1):150–156. doi: 10.1016/j.jss.2013.09.008.
   PubMed Web of Science ®Google Scholar
• Holm PS, Bergmann S, Jurchott K, et al. YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J Biol Chem. 2002;277(12):10427–10434. doi: 10.1074/jbc.M106955200.
   PubMed Web of Science ®Google Scholar
• Sutherland BW, Kucab J, Wu J, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage independent growth of breast cancer cells. Oncogene 2005;24(26):4281–4292. doi: 10.1038/sj.onc.1208590.
   PubMed Web of Science ®Google Scholar
• Kosnopfel C, Sinnberg T, Schittek B. Y-box binding protein 1-a prognostic marker and target in tumour therapy. Eur J Cell Biol. 2014;93(1–2):61–70. doi: 10.1016/j.ejcb.2013.11.007.
   PubMed Web of Science ®Google Scholar
• Raffetseder U, Frye B, Rauen T, et al. Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selection. J Biol Chem. 2003;278(20):18241–18248. doi: 10.1074/jbc.M212518200.
   PubMed Web of Science ®Google Scholar
• Evdokimova V, Ruzanov P, Imataka H, et al. The major mRNA-associated protein YB-1 is a potent 5' cap-dependent mRNA stabilizer. EMBO J. 2001;20(19):5491–5502. doi: 10.1093/emboj/20.19.5491.
   PubMed Web of Science ®Google Scholar
• Capowski EE, Esnault S, Bhattacharya S, Malter JS. Y box binding factor promotes eosinophil survival by stabilizing granulocyte-macrophage colony-stimulating factor mRNA. J Immunol. 2001;167(10):5970–5976. doi: 10.4049/jimmunol.167.10.5970.
   PubMed Web of Science ®Google Scholar
• Bargou RC, Jurchott K, Wagener C, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997;3(4):447–450. doi: 10.1038/nm0497-447.
   PubMed Web of Science ®Google Scholar
• Marino-Ramirez L, Spouge JL, Kanga GC, Landsman D. Statistical analysis of over-represented words in human promoter sequences. Nucleic Acids Res. 2004;32(3):949–958. doi: 10.1093/nar/gkh246.
   PubMed Web of Science ®Google Scholar
• Stratford AL, Habibi G, Astanehe A, et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res. 2007;9(5):R61.
   PubMed Web of Science ®Google Scholar
• Shibata T, Kan H, Murakami Y, et al. Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. Mol Cancer Ther.2013;12(5):737–746. doi: 10.1158/1535-7163.MCT-12-1125.
   PubMed Web of Science ®Google Scholar
• Ise T, Nagatani G, Imamura T, et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 1999;59:342–346.
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Rancso C, Stuhmer T, et al. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood. 2008;111(7):3714–3722. doi: 10.1182/blood-2007-05-089151.
   PubMed Web of Science ®Google Scholar